Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Josef J Fox

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Radiology|March 19, 2015
ResponseHebert Alberto Vargas, Cecilia Wassberg, Josef J Fox, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 11, 2011
Practical approach for comparative analysis of multilesion molecular imaging using a semiautomated program for PET/CTJosef J Fox, Estelle Autran-Blanc, Michael J Morris, et al.
Frontiers in Oncology|February 26, 2024
Online searches for hepatocellular carcinoma drugs mirror prescription trends across specialties and changes in guideline recommendationsPhilipp Berning, Adrian E Schroer, Rishav Adhikari, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 7, 2025
Lesion Absorbed Dose-Response Relationship in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [<sup>177</sup>Lu]Lu-PSMA-617 Radiopharmaceutical TherapyMilan Grkovski, Simone S Krebs, Joseph A O'Donoghue, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2013
Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancerDana E Rathkopf, Michael J Morris, Josef J Fox, et al.
Neuroendocrinology|May 24, 2022
Treatment Response and Clinical Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors to Lutetium-177-DOTATATENitya Raj, Kelley Coffman, Tiffany Le, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 6, 2025
Symptomatic Prostate-Specific Membrane Antigen PET-Positive Radionecrosis After Multimodality Brain Metastasis-Directed Treatment Including [<sup>177</sup>Lu]Lu-PSMA-617Brandon S Imber, Kenny Kwok Hei Yu, Wassim Abida, et al.
Clinical and Translational Imaging|February 12, 2025
Epichaperome-targeted myocardial imaging by <sup>124</sup>I-PU-H71 PETSonia Mahajan, Milan Grkovski, Kevin D Staton, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 5, 2019
Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using <sup>89</sup>Zr-DFO-MSTP2109A Anti-STEAP1 AntibodyJorge A Carrasquillo, Bernard M Fine, Neeta Pandit-Taskar, et al.
Molecular Pharmaceutics|May 24, 2019
Pharmacokinetics and Biodistribution of a [<sup>89</sup>Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer PatientsJoseph A O'Donoghue, Daniel C Danila, Neeta Pandit-Taskar, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Radiology|March 19, 2015
ResponseHebert Alberto Vargas, Cecilia Wassberg, Josef J Fox, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 11, 2011
Practical approach for comparative analysis of multilesion molecular imaging using a semiautomated program for PET/CTJosef J Fox, Estelle Autran-Blanc, Michael J Morris, et al.
Frontiers in Oncology|February 26, 2024
Online searches for hepatocellular carcinoma drugs mirror prescription trends across specialties and changes in guideline recommendationsPhilipp Berning, Adrian E Schroer, Rishav Adhikari, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 7, 2025
Lesion Absorbed Dose-Response Relationship in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [<sup>177</sup>Lu]Lu-PSMA-617 Radiopharmaceutical TherapyMilan Grkovski, Simone S Krebs, Joseph A O'Donoghue, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2013
Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancerDana E Rathkopf, Michael J Morris, Josef J Fox, et al.
Neuroendocrinology|May 24, 2022
Treatment Response and Clinical Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors to Lutetium-177-DOTATATENitya Raj, Kelley Coffman, Tiffany Le, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 6, 2025
Symptomatic Prostate-Specific Membrane Antigen PET-Positive Radionecrosis After Multimodality Brain Metastasis-Directed Treatment Including [<sup>177</sup>Lu]Lu-PSMA-617Brandon S Imber, Kenny Kwok Hei Yu, Wassim Abida, et al.
Clinical and Translational Imaging|February 12, 2025
Epichaperome-targeted myocardial imaging by <sup>124</sup>I-PU-H71 PETSonia Mahajan, Milan Grkovski, Kevin D Staton, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 5, 2019
Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using <sup>89</sup>Zr-DFO-MSTP2109A Anti-STEAP1 AntibodyJorge A Carrasquillo, Bernard M Fine, Neeta Pandit-Taskar, et al.
Molecular Pharmaceutics|May 24, 2019
Pharmacokinetics and Biodistribution of a [<sup>89</sup>Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer PatientsJoseph A O'Donoghue, Daniel C Danila, Neeta Pandit-Taskar, et al.
Pageof 4